Disease caused by non-tuberculous mycobacteria in children with cystic fibrosis

Paediatric Respiratory Reviews

Volumn 29, Issue , 2019, Pages 42-52

  Lu, Mimi ^a   Saddi, Vishal ^a   Britton, Philip N ^a,b   Selvadurai, Hiran ^a,b   Robinson, Paul D ^a,b   Pandit, Chetan ^a,b   Marais, Ben J ^a,b   Fitzgerald, Dominic A ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cystic fibrosis; Infection control; Lung disease; Non tuberculous mycobacteria (NTM); Prognosis; Treatment

Indexed keywords

AMIKACIN; AZITHROMYCIN; BEDAQUILINE; CEFOXITIN; CLARITHROMYCIN; CLOFAZIMINE; COTRIMOXAZOLE; CREATININE; DOXYCYCLINE; ETHAMBUTOL; IMIPENEM; LINEZOLID; LIVER ENZYME; MEROPENEM; MINOCYCLINE; MOXIFLOXACIN; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TIGECYCLINE; ANTIINFECTIVE AGENT;

AGITATION; ANEMIA; ANTIBIOTIC THERAPY; ANXIETY; ARTHRALGIA; ATYPICAL MYCOBACTERIOSIS; AUSTRALIA; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM DETECTION; CHILL; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; CYSTIC FIBROSIS; DIARRHEA; DIETARY INTAKE; DISEASE TRANSMISSION; DIZZINESS; DRUG METABOLISM; ENTEROPATHY; EOSINOPHILIA; EPIDEMIC; FEVER; HEADACHE; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEPATITIS; HIGH FREQUENCY HEARING LOSS; HUMAN; HYPERBILIRUBINEMIA; HYPOPROTEINEMIA; INFECTION CONTROL; INSOMNIA; IRIDOCYCLITIS; KIDNEY FAILURE; LABORATORY TECHNIQUE; LEUKOPENIA; LIFE EXPECTANCY; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; OPTIC NEURITIS; PANCREATIC INSUFFICIENCY; PANCREATITIS; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PHYSICAL DISEASE BY COMPOSITION OF BODY FLUIDS, EXCRETA AND SECRETIONS; PREVALENCE; PRIORITY JOURNAL; QT PROLONGATION; RASH; REVIEW; SCLERA DISEASE; SIDE EFFECT; SKIN DISCOLORATION; SURGICAL TECHNIQUE; TENDINITIS; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TINNITUS; TREATMENT DURATION; VASCULAR ACCESS; VERTIGO; VOMITING; ATYPICAL MYCOBACTERIUM; CHILD; MYCOBACTERIUM ABSCESSUS;

ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; HUMANS; LUNG TRANSPLANTATION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; PREVALENCE;

EID: 85057052196     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2018.05.001     Document Type: Review

References (88)

1. Qvist, T., et al. Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis. Respir Res, 15(1), 2014, 41.
2. Aitken, M.L., et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med 185:2 (2012), 231–232.
3. Bryant, J.M., et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. The Lancet 381:9877 (2013), 1551–1560.
4. Aitken, M.L., et al. Nontuberculous mycobacterial disease in adult cystic fibrosis patients. Chest 103:4 (1993), 1096–1099.
5. Esther, C.R., et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 9:2 (2010), 117–123.
6. Fauroux, B., et al. Mycobacterial lung disease in cystic fibrosis: a prospective study. Pediatr Infect Dis J 16:4 (1997), 354–358.
7. Hjelt, K., et al. The role of mycobacteria other than tuberculosis (MOTT) in patients with cystic fibrosis. Scand J Infect Dis 26:5 (1994), 569–576.
8. Hjelte, L., et al. Prospective study of mycobacterial infections in patients with cystic fibrosis. Thorax 45:5 (1990), 397–400.
9. Kilby, J.M., et al. Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest 102:1 (1992), 70–75.
10. Levy, I., et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis, 14(3), 2008, 378.
11. Moon, S.M., et al. Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease. Antimicrob Agents Chemother 60:11 (2016), 6758–6765.
12. Mussaffi, H., et al. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J 25:2 (2005), 324–328.
13. Oliver, A., et al. Nontuberculous mycobacteria in patients with cystic fibrosis. Clin Infect Dis 32:9 (2001), 1298–1303.
14. Olivier, K.N., et al. Nontuberculous mycobacteria: I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 167:6 (2003), 828–834.
15. Pierre-Audigier, C., et al. Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J Clin Microbiol 43:7 (2005), 3467–3470.
16. Radhakrishnan, D.K., et al. Non-tuberculous mycobacteria in children with cystic fibrosis: isolation, prevalence, and predictors. Pediatr Pulmonol 44:11 (2009), 1100–1106.
17. Roux, A.-L., et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in France. J Clin Microbiol 47:12 (2009), 4124–4128.
18. Sermet-Gaudelus, I., et al. Mycobacterium abscessus and children with cystic fibrosis. Emerg Infect Dis, 9(12), 2003, 1587.
19. Smith, M., et al. Mycobacterial isolations in young adults with cystic fibrosis. Thorax 39:5 (1984), 369–375.
20. Valenza, G., et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 7:2 (2008), 123–127.
21. Qvist, T., et al. Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. J Cyst Fibros 14:1 (2015), 46–52.
22. Hoefsloot, W., et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J 42:6 (2013), 1604–1613.
23. Prevots, D.R., et al. Environmental risks for nontuberculous mycobacteria. Individual exposures and climatic factors in the cystic fibrosis population. Ann Am Thorac Soc 11:7 (2014), 1032–1038.
24. Adjemian, J., et al. Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am J Respir Crit Care Med 186:6 (2012), 553–558.
25. Ingen, J., Wagner, D., Epidemiology of nontuberculous mycobacterial disease in Germany and worldwide. Pneumologie, 8(6), 2011, 396.
26. Chou, M.P., Clements, A.C., Thomson, R.M., A spatial epidemiological analysis of nontuberculous mycobacterial infections in Queensland, Australia. BMC Infect Dis, 14(1), 2014, 279.
27. Whittier, S., et al. Proficiency testing of clinical microbiology laboratories using modified decontamination procedures for detection of nontuberculous mycobacteria in sputum samples from cystic fibrosis patients. The Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. J Clin Microbiol 35:10 (1997), 2706–2708.
28. Brown-Elliott, B.A., Nash, K.A., Wallace, R.J., Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev 25:3 (2012), 545–582.
29. Wu, B., et al. Evaluation of the airway microbiome in non-tuberculous Mycobacteria. Am J Respir Crit Care Med, 193, 2016, A7497.
30. Mauch, R.M., et al. Association of growth and nutritional parameters with pulmonary function in cystic fibrosis: a literature review. Rev Paul Pediatr 34:4 (2016), 503–509.
31. Davis, P.B., Cystic fibrosis since 1938. Am J Respir Crit Care Med 173:5 (2006), 475–482.
32. Sims, G., The Australian cystic fibrosis data registry. 2015, Improving Healthcare p. 201524.
33. Stephenson, A.L., et al. Survival comparison of patients with cystic fibrosis in Canada and the United States: a population-based cohort study. Ann Intern Med 166:8 (2017), 537–546.
34. Griffith, D.E., Emergence of nontuberculous mycobacteria as pathogens in cystic fibrosis. Am Thorac Soc, 2003.
35. Jagielski, T., et al. Current methods in the molecular typing of Mycobacterium tuberculosis and other mycobacteria. Biomed Res Int, 2014, 2014.
36. De Bel, A., et al. Sampling and decontamination method for culture of nontuberculous mycobacteria in respiratory samples of cystic fibrosis patients. J Clin Microbiol 51:12 (2013), 4204–4206.
37. Falkinham, J.O. III, Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis, 17(3), 2011, 419.
38. Ovrutsky, A.R., et al. Cooccurrence of free-living amoebae and nontuberculous Mycobacteria in hospital water networks, and preferential growth of Mycobacterium avium in Acanthamoeba lenticulata. Appl Environ Microbiol 79:10 (2013), 3185–3192.
39. Primm, T.P., Lucero, C.A., Falkinham, J.O., Health impacts of environmental mycobacteria. Clin Microbiol Rev 17:1 (2004), 98–106.
40. Nishiuchi, Y., et al. The recovery of Mycobacterium avium-intracellulare complex (MAC) from the residential bathrooms of patients with pulmonary MAC. Clin Infect Dis 45:3 (2007), 347–351.
41. Bange, F.-C., et al. Lack of transmission of Mycobacterium abscessus among patients with cystic fibrosis attending a single clinic. Clin Infect Dis 32:11 (2001), 1648–1650.
42. Bryant, J.M., et al. Population-level genomics identifies the emergence and global spread of a human transmissible multidrug-resistant nontuberculous mycobacterium. Science (New York, NY), 354(6313), 2016, 751.
43. Harris, K.A., et al. Whole-genome sequencing and epidemiological analysis do not provide evidence for cross-transmission of Mycobacterium abscessus in a cohort of pediatric cystic fibrosis patients. Clin Infect Dis 60:7 (2014), 1007–1016.
44. Boyce, J.M., Pittet, D., Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Am J Infect Control 30:8 (2002), S1–S46.
45. Saiman, L., et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 35:S1 (2014), s1–s67.
46. Griffith, D.E., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175:4 (2007), 367–416.
47. Jeon, K., et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 180:9 (2009), 896–902.
48. Renna, M., et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Investig 121:9 (2011), 3554–3563.
49. Binder, A.M., et al. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 188:7 (2013), 807–812.
50. Catherinot, E., et al. Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients. Eur Respir J 41:5 (2013), 1101–1106.
51. Martiniano, S.L., et al. Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thoracic Soc 11:1 (2014), 36–44.
52. Floto, R.A., et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 71:Suppl 1 (2016), i1–i22.
53. Kerem, E., et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 326:18 (1992), 1187–1191.
54. Liou, T.G., et al. Year-to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros 9:4 (2010), 250–256.
55. Schluchter, M.D., Konstan, M.W., Davis, P.B., Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med 21:9 (2002), 1271–1287.
56. Qvist, T., et al. Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis. J Cyst Fibros 15:3 (2016), 380–385.
57. Haworth, C.S., et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 72:Suppl 2 (2017), ii1–ii64.
58. Lyu, J., et al. Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. Respir Med 105:5 (2011), 781–787.
59. Lyu, J., et al. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease. Respir Med 108:11 (2014), 1706–1712.
60. Waters, V., Ratjen, F., Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev, 12, 2014.
61. Olivier, K.N., et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med 195:6 (2017), 814–823.
62. Adékambi, T., et al. rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol 56:1 (2006), 133–143.
63. Nash, K.A., Brown-Elliott, B.A., Wallace, R.J., A novel gene, erm (41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 53:4 (2009), 1367–1376.
64. Choi, G.-E., et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 186:9 (2012), 917–925.
65. Maurer, F.P., et al. Erm (41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. J Antimicrob Chemother 69:6 (2014), 1559–1563.
66. Ballarino, G.J., et al. Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med 103:10 (2009), 1448–1455.
67. Koh, W.-J., et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 183:3 (2011), 405–410.
68. DaCosta, A., et al. Outcomes associated with antibiotic regimens for treatment of Mycobacterium abscessus in cystic fibrosis patients. J Cyst Fibros 16:4 (2017), 483–487.
69. World Health Organization, Treatment of Tuberculosis Guidelines, 4th ed., 2010.
70. Jarand, J., et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 52:5 (2011), 565–571.
71. Corey, M., et al. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 41:6 (1988), 583–591.
72. Hollander, F., et al. Effects of nutritional status and dietetic interventions on survival in Cystic Fibrosis patients before and after lung transplantation. J Cyst Fibros 13:2 (2014), 212–218.
73. Park, J., et al. Progression and treatment outcomes of lung disease caused by Mycobacterium abscessus and Mycobacterium massiliense. Clin Infect Dis, 2016, 723.
74. Chalermskulrat, W., et al. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 61:6 (2006), 507–513.
75. Lobo, L.J., et al. Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections. Clin Transplant 27:4 (2013), 523–529.
76. Qvist, T., et al. Nontuberculous mycobacterial disease is not a contraindication to lung transplantation in patients with cystic fibrosis: a retrospective analysis in a Danish patient population. Transplantation Proceedings, 2013, Elsevier.
77. Jamal, W., et al. An outbreak of Mycobacterium abscessus infection in a Pediatric Intensive Care Unit in Kuwait. Pediatr Infect Dis J 33:3 (2014), e67–e70.
78. Kapnadak, S.G., et al. Infection control strategies that successfully controlled an outbreak of Mycobacterium abscessus at a cystic fibrosis center. Am J Infect Control 44:2 (2016), 154–159.
79. Strollo, S.E., et al. The burden of pulmonary nontuberculous mycobacterial disease in the United States. Ann Am Thoracic Soc 12:10 (2015), 1458–1464.
80. Leber, A., Marras, T., The cost of medical management of pulmonary nontuberculous mycobacterial disease in Ontario, Canada. Eur Respir J 37:5 (2011), 1158–1165.
81. Harausz, E.P., et al. New and repurposed drugs for pediatric multidrug-resistant tuberculosis. Practice-based recommendations. Am J Respir Crit Care Med 195:10 (2017), 1300–1310.
82. Marais, B.J., Schaaf, H.S., Graham, S.M., Child health and tuberculosis. Lancet Respir Med 2:4 (2014), 254–256.
83. Sawicki, G.S., Sellers, D.E., Robinson, W.M., High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 8:2 (2009), 91–96.
84. Hegarty, M., et al. Quality of life in young people with cystic fibrosis: effects of hospitalization, age and gender, and differences in parent/child perceptions. Child Care Health Dev 35:4 (2009), 462–468.
85. Duff, A., Psychological consequences of segregation resulting from chronic Burkholderia cepacia infection in adults with CF. 2002, BMJ Publishing Group Ltd.
86. Saiman, L., Siegel, J., Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 24:S5 (2003), S6–S52.
87. Yaacoby-Bianu, K., Gur, M., Toukan, Y., Nir, V., Hakim, F., Geffen, Y., Bentur, L., Compassionate nitric oxide adjuvant treatment of persistent mycobacterium infection in cystic fibrosis patients. Pediatr Infect Dis J 37 (2018), 336–338.
88. Deppisch, C., et al. Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study. Infection 44:4 (2016), 513–520.